Tevogen Bio Holdings (FRA:G28) ROCE % : 0.00% (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Tevogen Bio Holdings's annualized ROCE % for the quarter that ended in Sep. 2024 was 0.00%.

Tevogen Bio Holdings ROCE % Historical Data

The historical data trend for Tevogen Bio Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings ROCE % Chart

Tevogen Bio Holdings Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-214.57

2.43

0.10

Tevogen Bio Holdings Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial					-	1,600.40	1,086.14	-	-

Tevogen Bio Holdings ROCE % Calculation

Tevogen Bio Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	0.173	/	( ( (337.138 - 0.33)	+	(15.623 - 2.755) )	/ 2 )
	=	0.173	/	( (336.808	+	12.868)	/ 2 )
	=	0.173	/	174.838
	=	0.10 %

Tevogen Bio Holdings's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-21.164	/	( ( (3.075 - 9.859)	+	(3.864 - 9.385) )	/ 2 )
	=	-21.164	/	( ( -6.784	+	-5.521 )	/ 2 )
	=	-21.164	/	-6.1525
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Tevogen Bio Holdings (FRA:G28) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Tevogen Bio Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tevogen Bio Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (FRA:G28) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TVGN:USA G28:Germany

Address

15 Independence Boulevard, Warren, NJ, USA, 07059

Website

https://www.tevogen.com

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Headlines

No Headlines